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Abstract The objective of this study was to assess the
budget impact and health effects of introducing rotavirus
(RV) vaccination in Saxony, Germany, from a health
insurance perspective. Special emphasis is given to the
herd effect. We analyzed direct medical and non-medical
costs of RV infection for Social Health Insurance between
2007 and 2010 based on 360,000 routine data observations
from the AOK PLUS for children below 5 years of age. We
compared the actual annual number of RV cases (vacci-
nation scenario) with the number derived from 2005 (no
vaccination, base case scenario). The vaccination coverage
rate has increased from 5 % to 61 % between 2007 and
2010. The number of RV cases decreased by 21 % from
32,274 in 2007 to 25,614 in 2010. Based on vaccination
coverage, the total cost savings per 1,000 children due to
RV vaccination was estimated to be 39,686 Euros. The
overall share of outpatient costs was 60 %. Mean gross cost
savings were expected to be 304 Euros per avoided case.
The net cost savings were expected to be 19 Euros per
avoided case. About 59 % of total savings was due to herd
protection resulting from increasing vaccine rates. The herd
effect per avoided case increased with increasing vaccine
coverage. Incidence of RV cases, vaccination costs and
days absent from work were sensitive parameters. This
retrospective analysis showed that the increase in RV
vaccination coverage in Saxony has been budget neutral if
not cost saving for sick funds.
Keywords Rotavirus  Vaccination  Germany  Herd
effect  Budget impact analysis
JEL Classification H51  I13  I18
Introduction
In Germany, rotavirus (RV) was the third most commonly
reported cause of acute gastroenteritis (GE) during 2005
and 2010 and was the leading cause of acute GE in the last
decade in children below 5 years of age [1]. In Germany,
laboratory-confirmed RVGE has been a notifiable disease
since 2001 [1, 2]. In industrialized countries RVGE does
not lead to death; however, the burden of RVGE disease
remains considerable resulting in frequent outpatient visits
and hospitalization. Consequently, the medical and eco-
nomic burden associated with RVGE in these countries is
high [3–7]. As with other developed nations, RVGE dis-
ease burden constitutes a significant public health problem
in Germany [1, 2, 6, 7]. Of the total number of RVGE cases
reported in Germany in children below 5 years of age,
57 % were hospitalized [2, 8].
Two orally administered RV vaccines, which have
demonstrated to have good efficacy and safety in global
clinical trials, have been licensed in most countries: Ro-
tarix (GlaxoSmithKline Vaccines, Wavre, Belgium) and
RotaTeq (Merck, Whitehouse Station, NJ) [9–12]. These
vaccines were licensed by the European Medicines
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Agency (EMA) for use in Europe in 2006 [5, 13]. Ro-
tarix and RotaTeq are available in a two- and three-
dose schedule, respectively. The vaccine doses are pre-
scribed as follows: the first dose is given to children from
the age of 6 weeks until 24 weeks for Rotarix and
32 weeks of age for RotaTeq. In 2009, the World Health
Organization (WHO) recommended that vaccination
against RV should be implemented through universal
routine immunization of infants. Additionally, establish-
ment of surveillance systems to monitor vaccine impact
where RV vaccines are available was also included in the
WHO recommendation [14, 15].
Since the availability of RV vaccines in Germany, RV
vaccination coverage across the federal states in Germany
has increased steadily and reached 25 % in 2010 [3]. In
Saxony, 61 % of all children were vaccinated against RV
in the same year [16]. Five federal states of Germany,
including Saxony, have been releasing local vaccine rec-
ommendations for the prevention of RVGE disease in
young children. A recommendation for routine rotavirus
of the German Standing Committee on Vaccination
(STIKO) has been published in 2013 [17]. At the time
this analyses was initiated health insurances companies
were therefore not obliged to reimburse vaccination costs
[8].
To assess the economic effects of RV vaccination,
cost-effectiveness analyses based on Markov cohort
models are typically used (see e.g., Standaert et al. [18]
for RV hospitalizations in Belgium [18]). Despite the
presence of an adequate infrastructure and a robust sur-
veillance system in place in Germany [1, 8], there is
limited evidence on the cost benefit of implementation of
RV vaccination [16], especially from the payer perspec-
tive. The aim of this analysis was therefore to quantify
the financial effects of the implementation of universal
RV vaccination in Saxony based on observed RV cases,
with emphasis on the direct effects of vaccination and
protection induced from herd effects as a positive exter-
nality of vaccination coverage.
Methods
Model structure
We performed a retrospective budget impact analysis
(BIA) on the implementation of RV vaccination in Saxony
from the Statutory Health Insurance (SHI) perspective. We
evaluated the benefits of implementation of RV vaccination
(two-dose schedule) in children below 5 years of age
including protection conferred as a result of herd effect.
The BIA was quantified by a comparison of costs between
base case and vaccine scenario. Total cost savings (in
Euros) per 1,000 children and cost savings (in Euros) per
avoided case were estimated. Cost savings were also esti-
mated for both inpatient and outpatient groups and quan-
tified separately due to herd and direct effects of
vaccination. We conducted the analysis in MS Excel via a
three step approach:
1. Calculation of inpatient and outpatient cases and
associated costs based on AOK PLUS data.
2. Extrapolation of RV cases in base case scenario.
3. Comparison of vaccination scenario and base case
scenario on in- and out-patient cases as well as
associated costs.
4. Deduction and estimation of observed herd effect.
Input data
Epidemiological data
The RV cases selected for the present analysis are based on
data from a statutory German health insurer—AOK PLUS
[19]. About 55 % of Saxon children from the 1st until the
5th year of life are insured by AOK PLUS. We analyzed a
relatively large data set for the vaccination scenario that
was based on 360,000 observations including number of
cases and costs per case of RVGE for the years 2007–2010
for both inpatient and outpatient settings.
In Germany, laboratory-confirmed RV infections are
notifiable. However, mild and moderate infections are
often managed at home without consulting a physician. In
case of treatment physicians usually do not perform testing
[20]. As a result, the number of notified cases is much
lower than annual incidence rates reported in the literature
[4, 21–24]. Hence, reported RV infections are likely to
underestimate the true number of cases [25]. Therefore our
AOK PLUS observations included the following diagnoses
according to the International Classification of Diseases,
Tenth Revision (ICD-10) codes 2011: A08.0: Rotaviral
enteritis, A08.3: Other viral enteritis, A08.4: Viral intesti-
nal infection, unspecified and A09: Infectious gastroen-
teritis and colitis, unspecified. A case of RVGE for the
purpose of this analysis was defined as one or more treat-
ments of an insured person by the same physician within a
quarter of a year (i.e., even if an insured person received
more than one treatment within the same quarter of a year,
this will be handled as one case only).
With the given data we could not identify whether a
specific child received outpatient or inpatient treatment
within the same quarter of the year. Consequently, our data
does not represent the actual number of patients but rather
the number of cases registered in each of the two treatment
groups, i.e., outpatient and inpatient group. It should also
be noted that the inpatient group includes the patient
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contact to emergency. Statistical methods to differentiate
cases are not available, but we refer to Giaquinto et al. [2],
stating that contact with emergency is always associated
with hospitalization.
Since the time period in the AOK PLUS data set was
limited to 2007–2010, we also used data from the Robert-
Koch-Institut (RKI) [26] for Saxony to calculate the per-
centage increase in RVGE numbers for the years
2003–2007. It is important to note that cases identified
from the RKI include only the diagnosis ICD-10 code
A08.0: Rotaviral enteritis. Sources for the input data are
given in Table 1.
Costs
Our BIA was limited to the evaluation of costs from the
SHI payer perspective. The different types of costs were
calculated using data from the Federal Statistical Office,
the Statistical Office of Saxony and AOK PLUS.
Moreover, we used cost data from the REVEAL study [2],
which analyzed the costs and burden of RV infection in
another East German Federal State (Mecklenburg-Vor-
pommern in 2004). Figure 1 shows the total costs per case
from the SHI perspective, including direct medical and
non-medical costs as well as the costs for vaccination. As
expected, inpatient cases are more expensive than outpa-
tient ones. The cost structure to determine total costs per
case are explained below.
Direct medical costs The data set of AOK PLUS
allowed for the analysis of average direct medical costs
per age group, and for inpatient and outpatient treatment
groups. The included cost categories, for example med-
ication and physician visits, could not be specified any
further because the data set contained only the total
medical costs. From the age-group-specific costs we get
average costs per case by weighting according to age
distribution (Table 2).
Table 1 Input data
RV Rotavirus, RKI Robert-
Koch-Institut
Input factor Source/assumption
Population Statistical Office of Saxony
Vaccination coverage [3, 16]
RV cases, vaccine scenario (2007–2010) AOK PLUS data set [19]
RV cases, base case scenario (2007–2010) AOK PLUS cases from 2007 counted back
to 2005, then calculation of hypothetical cases
(2007–2010) using average RKI growth rates
(2001–2007)
Percentage annual increase in RV cases (2001–2007) RKI data set [26]
Direct medical costs AOK PLUS [19]
Direct non-medical costs (sickness-benefits)
Rate of employment of mothers Statistical Office of Saxony [36]
Wage Statistical Office of Saxony [27]
Days of absence from work Giaquinto et al. [2]
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Fig. 1 Costs per rotavirus (RV) case from a statutory health insurance (SHI) perspective in 2010
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Direct non-medical costs (sickness benefit) We assumed
that the professional working mother stayed at home during
the time of inpatient or outpatient treatment of her child. In
Germany, health insurers have to pay sickness benefits to
the parent during absence from work. The proportions of
mothers in Saxony with children in the relevant age groups
who are working professionals are shown in Table 3. The
average number of days of leave of the parent from work
due to RV infection of the child were assumed as follows:
outpatient cases 5.3 days and inpatient cases 6.4 days.
These data refer to survey results of the REVEAL study
and are limited to the urban population of Rostock between
2004 and 2005 [2]. To determine the sickness benefits, we
used the average gross wage per female employee
(20–45 years) in Saxony in 2010 of 102.87 (full-time) and
71.13 (part-time) Euro per day in 2010 (Statistical Office of
Saxony [27]). As the amount of sickness benefits depends
on the net wage, we calculated the net wage for Saxony as
two-thirds of the average gross wage. This value was
deflated for the years 2007 to 2009 at an average rate of
2 % corresponding to economic development [28].
Assuming a sickness benefit of 75 %, the costs were cal-
culated as follows:
Sickness benefits year; age ¼ 0:75 net wage year; age
 days absent fromwork
 rate of employment of mothers age
Costs of vaccination The total vaccination cost of 124
Euro included—for a two-dose schedule—the cost of
vaccine of 58.53 Euros per dose (taken from a pack with
one dose, [29]) and a medical fee of 6.50 Euros [30].
Vaccine scenario
The vaccine scenario represents the actual number of RV
cases reported subsequent to the implementation of RV
vaccination in Saxony in 2006 which is given by the AOK
PLUS data set for the years 2007 to 2010. It was observed
that both the numbers of inpatient and outpatient RV cases
decreased significantly post-introduction of RV vaccines in
2006. Additionally, we calculated the incidence rate per
age group and the probabilities of the RV case seeking
outpatient or inpatient care (Table 4). Table 4 presents the
vaccination coverage for the years 2007–2010 in Saxony.
Given the number of insured children, we estimated the
number of unprotected children. We assumed for the
present analysis that immunization is effective for 2 years.
Table 2 Economic burden associated with RV infection (Euros per case) and vaccination costs
Year 2007 2008 2009 2010
Treatment group Inpatient Outpatient Inpatient Outpatient Inpatient Outpatient Inpatient Outpatient
Age group
Direct medical costs
0–1 years 1,737 85 1,758 64 1,813 73 1,849 76
1–2 years 1,429 66 1,593 49 1,623 53 1,712 56
2–3 years 1,409 55 1,555 45 1,621 50 1,680 52
3–4 years 1,304 48 1,468 42 1,471 48 1,463 50
4–5 years 1,294 46 1,409 44 1,441 48 1,461 49
Average BS 1,508 60 1,614 48 1,652 53 1,700 55
Average VS 1,517 61 1,618 48 1,656 53 1,707 55
Direct non-medical costs (sickness benefits, kinderkrankengeld)
0–1 years 153 126 156 129 159 132 162 134
1–2 years 152 126 155 128 158 131 161 133
2–3 years 163 135 166 138 170 141 173 143
3–4 years 173 144 177 146 180 149 184 152
4–5 years 175 145 179 148 183 151 186 154
Costs of vaccination 124 124 124 124
Table 3 Percentage of mothers in Saxony who are working profes-
sionals [34]








0–1 52.7 77 23
1–2 54.5 64 36
2–3 59.6 60 40
3–4 31.5 59 41
4–5 65.4 58 42
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We excluded any vaccine waning effect as previous studies
have demonstrated its absence in real life conditions as
well as a high vaccine efficacy in clinical trials of nearly
100 % [9–11, 18]. Given the distribution of vaccinated
children per year, we assume that 80 % of the children are
protected during the first year of life. This is based on the
fact that the children are not vaccinated immediately at the
time of birth, but on an average 2 and 4 months of age.
Therefore, we estimated 100 % protection for children of
ages between 1 and 2 years and 20 % protection for chil-
dren of ages between 2 and 3 years. We estimated the
incidence rates as ratio of inpatient or outpatient RV cases
and unprotected children (Table 4).
Base case scenario
To calculate the net effect of the vaccination program in
Saxony we developed a hypothetical data set. The base case
scenario considered hypothetical cases that would have
occurred between 2007 and 2010 without a vaccination
program. For this, we used data from RKI (Table 5) for
Saxony, since the data ofAOKPLUS are available only from
2007 until 2010. In detail, the base case scenario was built on
the assumption that the growth rates of RKI cases are iden-
tical with that of AOK PLUS. According to these growth
rates, no up- or down-ward trend can be identified for the
period prior to the introduction of the vaccine (Table 5).
Table 4 Vaccine scenario: AOK PLUS data set for Saxony, 2007–2010
Insured children Number of RVGE cases
Age group/year (n) 2007 2008 2009 2010
0–1 years 19,094 19,044 18,093 17,970
1–2 years 18,759 19,094 19,044 18,093
2–3 years 18,240 18,759 19,094 19,044
3–4 years 17,776 18,240 18,759 19,094
4–5 years 16,484 17,776 18,240 18,759
Overall 90,353 92,913 93,230 92,960
Vaccination coverage (%) 2007 2008 2009 2010
5 35 52 61
Unprotected children (n) 2007 2008 2009 2010
0–1 years 18,330 13,712 10,566 9,201
1–2 years 18,759 18,139 12,379 8,685
2–3 years 18,240 18,759 18,903 17,711
3–4 years 17,776 18,240 18,759 19,094
4–5 years 16,484 17,776 18,240 18,759
Overall 89,589 86,626 78,847 73,449
Vaccinated children (n) 2007 2008 2009 2010
955 6,665 9,408 10,962
RV cases (A08.0, A08.3, A08.4, A09) (calculated incidence rates)
Year 2007 2008 2009 2010
Age/treatment
group
Inpatient Outpatient Inpatient Outpatient Inpatient Outpatient Inpatient Outpatient
0–1 years 858 (0.05) 4,767 (0.26) 782 (0.06) 4,395 (0.32) 582 (0.06) 3,548 (0.34) 578 (0.06) 3,078 (0.33)
1–2 years 744 (0.04) 9,197 (0.49) 749 (0.04) 9,267 (0.51) 622 (0.05) 8,692 (0.70) 591 (0.07) 6,624 (0.76)
2–3 years 380 (0.02) 7,177 (0.39) 399 (0.02) 7,015 (0.37) 315 (0.02) 6,477 (0.34) 314 (0.02) 5,778 (0.33)
3–4 years 229 (0.01) 5,214 (0.29) 221 (0.01) 5,664 (0.31) 183 (0.01) 4,956 (0.26) 186 (0.01) 4,793 (0.25)
4–5 years 147 (0.01) 3,560 (0.22) 159 (0.01) 4,215 (0.24) 122 (0.01) 3,489 (0.19) 125 (0.01) 3,547 (0.19)
Overall 2,358 (0.03) 29,916 (0.33) 2,310 (0.03) 30,556 (0.35) 1,824 (0.02) 27,162 (0.34) 1,794 (0.02) 23,820 (0.32)
RVGE Rotavirus gastroenteritis
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Thus the incidence rates of RV cases were probably not
influenced by external factors. The following steps were
implemented in the construction of the base case scenario for
each age group (Table 6):
• To account for the seasonal fluctuation of RV cases
within the RKI data set we calculated a moving average
with a timespan of 5 years to derive adjusted case
values for the years 2005, 2006 and 2007.
• We computed the growth rates of RV cases for the
years 2006 and 2007.
• The actual numbers of RV cases from AOK PLUS from
2007 were counted back to 2005 by using the
Table 5 RKI data set: RV
cases (A08.0) in Saxony
Number of cases
Age group/year 2001 2002 2003 2004 2005 2006 2007 2008
0–1 years 1,051 1,682 1,877 1,383 1,941 2,096 1,794 1,485
1–2 years 2,085 1,989 1,924 1,445 2,352 2,508 2,172 2,256
2–3 years 1,183 1,065 968 643 1,064 1,262 1,072 1,278
3–4 years 632 639 530 346 594 615 541 723
4–5 years 391 383 260 216 424 374 318 443
Overall 5,342 5,758 5,559 4,033 6,375 6,855 5,897 6,185
Table 6 Construction of the base case scenario: RV cases in Saxony (RKI) or in AOK PLUS data set
Step 1: moving average = adjusted RKI cases per year 2005 2006 2007
2001–2005 2002–2006 2003–2007
0–1 years 1,587 1,796 1,818
1–2 years 1,959 2,044 2,080
2–3 years 985 1,000 1,002
3–4 years 548 545 525
4–5 years 335 331 318
Overall 5,413 5,716 5,744
Step 2: % annual increase in RV cases
0–1 years ?0.13 ?0.00
1–2 years ?0.04 ?0.01
2–3 years ?0.00 ?0.00
3–4 years -0.02 -0.05
4–5 years -0.03 -0.06
Average ?0.04 ?0.00
Step 3: counted-back AOK PLUS cases 2005 2006 2007
0–1 years 4,688 (in. = 703, out. = 3,985) 5,281 5,625
1–2 years 9,139 (in. = 640, out. = 8,500) 9,392 9,941
2–3 years 7,313 (in. = 366, out. = 6,947) 7,554 7,557
3–4 years 5,756 (in. = 230, out. = 5,525) 5,690 5,443
4–5 years 4,299 (in. = 172, out. = 4,127) 4,142 3,707
Overall 30,474 31,995 32,274
Step 4: incidence rates Inpatient Outpatient
0–1 years 0.04 0.22
1–2 years 0.04 0.47
2–3 years 0.02 0.39
3–4 years 0.01 0.32
4–5 years 0.01 0.24
Average 0.02 0.33
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previously calculated percentage increase of the RKI
cases. We assumed a constant distribution of inpatient
and outpatient cases (as observed in the AOK PLUS
data set for 2007–2010), following which we estimated
the number of cases in both the groups—inpatient and
outpatient for the year 2005.
• The simulated numbers of RV cases were considered to
infer the incidence rates of RV cases for Saxony in 2005 for
the inpatient and outpatient groups based on the total
number of insured childrenper age group.Weassume those
to be constant and therefore also valid for 2007 to 2010.
The base year 2005 was chosen because RV vaccines
were not licensed until 2006. Using the number of
insured children by AOK PLUS and the calculated
incidence rates, the hypothetical number of cases in the
base case scenario for the years 2007 to 2010 were
determined (Table 7).
Analyses
Base case versus vaccine scenario
The overall effect (RV cases and cost savings) of RV
vaccination, i.e., the difference between base case scenario
and vaccine scenario was reported for all children below
5 years of age. These effects were reported for both
Table 7 Base case scenario: derived hypothetical RV cases (no vaccine administered) in Saxony, 2007–2010
Year 2007 2008 2009 2010
Age/treatment group Inpatient Outpatient Inpatient Outpatient Inpatient Outpatient Inpatient Outpatient
0–1 years 1,329 7,532 1,351 7,656 1,337 7,576 1,331 7,544
1–2 years 1,140 15,145 1,187 15,772 1,208 16,050 1,203 15,982
2–3 years 673 12,792 672 12,761 700 13,293 697 13,237
3–4 years 438 10,515 429 10,294 429 10,301 427 10,257
4–5 years 315 7,569 326 7,819 319 7,662 318 7,629
Overall 3,962 53,911 3,974 54,558 3,946 54,990 3,888 54,450
Table 8 RV cases averted per
1,000 children
Year Category Avoided cases = total effect Due to herd effect Due to
direct effect
Age group Inpatient Outpatient Inpatient Outpatient
2007 0–1 years 0 (-5.7) 0 (-27.2) – – –
1–2 years 0 (-4.6) 0 (-24.5) – – –
2–3 years 0 (-0.2) 0 (-0.9) – – –
3–4 years 0.3 24.1 0.3 24.1 0
4–5 years 0.9 20.7 0.9 20.7 0
2008 0–1 years 0 (-1.8) 0 (-8.3) – – –
1–2 years 0 (-4.2) 0 (-19.5) – – –
2–3 years 0 (-0.6) 18.7 0 18.7 0
3–4 years 1.1 6.9 1.1 6.9 0
4–5 years 0.9 0 (-0.4) 0.9 0 0
2009 0–1 years 7.1 26.4 0 0 33.5
1–2 years 2.4 9.4 0 0 11.8
2–3 years 4.2 53.4 4.0 49.4 4.1
3–4 years 3.5 53.2 3.5 53.2 0
4–5 years 3.2 45.4 3.2 45.4 0
2010 0–1 years 7.1 51.2 0 0 58.3
1–2 years 2.4 99.7 0 0 102.1
2–3 years 4.2 89.2 2.7 61.7 29.0
3–4 years 3.5 66.4 3.5 66.4 0
4–5 years 3.2 47.6 3.2 47.6 0
2007–2010 44 612.3 23.3 394.1 238.8
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inpatient and outpatient settings as well as for children
segregated into five age groups (0–1, 1–2, 2–3, 3–4 and
4–5 years).
Calculation of vaccination effectiveness
The total effect of RV vaccination was calculated as:
Total effect¼RVcases (BS)  RVcases ðVS).
Herd effect and direct effect
The total effect due to vaccination can be seen as a result of
vaccine direct effects and due to herd protection. The direct
effect represents the expected direct cost savings for the
insurance. In general, the herd effect describes the reduc-
tion in infection probability of unvaccinated individuals as
a result of others in the same society being vaccinated [31].
Following that definition, we calculated the herd effect as
the difference between expected RV cases in the base case
scenario and actual RV cases in the vaccine scenario. It
was determined as follows:
Herd effect¼ rotavirus incidence ðBS)
 unprotected children actual rotavirus cases ðVS)
We implemented the following steps to quantify the
importance of herd effect for each age group:
• Calculation of RV incidence (BS) 9 unprotected
people (VS) as the hypothetical number of RV cases
if the incidence rate were unaffected by vaccination.
• Calculation of RV incidence (BS) 9 unprotected
people (VS)—actual RV cases (VS) as difference
between the previously calculated hypothetical cases
and the actual cases taken from the VS.
If actual RV cases exceeded the number of expected RV
cases, herd effect was set to zero. A positive difference
between the hypothetical and actual number of RV cases
implied a decrease in incidence for the VS and confirmed
immunization resulting from herd protection.
The direct effect results from
Direct effect ¼ Total effect Herd effect
which is the difference between the number of avoided
cases and the herd effect. If we derived a positive total
effect for the age groups 3–4 and 4–5 years, the total effect
was equal to the herd effect because direct protection
through vaccination is not feasible for these groups. Hence,
the direct effect is zero.
Sensitivity analyses
To account for the uncertainty in our assumptions or to
validate the robustness of our assumptions, we conducted a
univariate sensitivity analysis by varying the sensitive
parameters until the net cost savings faded out. The
hypothetical cases calculated within the base case scenario
are based on several assumptions. We assumed constant
incidence rates for the period 2007–2010 which were
estimated based on incidence rates of 2005 and which
resulted from a data set including only part of diagnoses
relevant for RV disease. Therefore, ‘‘data’’ variations in the
outpatient and inpatient incidence rate of ±0.5 and
±0.06 % were analyzed. Moreover, we analyzed a varia-
tion of ‘‘days of absence from work’’ of ±1 and ±4 days as
well as a decrease in vaccination costs of 15 %.
Results
Base case scenario versus vaccine scenario
Table 8 shows the number of RV cases avoided for all
children stratified by age group and year. As observed for
the years 2007 and 2008 for some age groups, the estimated
numbers of RV cases avoided are negative. As there is no
plausible explanation for negative signs from a medical
perspective, increasing awareness and changing commu-
nication about RV cases by medical professionals might
have caused higher numbers of RV cases registered in the
time period following the implementation of RV vaccina-
Fig. 2 Incidence of inpatient and outpatient RV cases per 1,000
children
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tion in Saxony. Indeed, for 2009, this effect no longer
exists, which can be explained by increasing effectiveness
of the vaccination program corresponding with a stronger
decrease of cases within the vaccine scenario. Figure 2
shows the time trend curve of inpatient and outpatient RV
cases for both the vaccine and the base case scenario
without differentiation of age groups. The figure shows the
actual data of both scenarios without the previously
explained correction of numbers. Both the numbers of
inpatient as well as the outpatient RV cases decreased
significantly in the vaccine scenario while these numbers
remained fairly constant in the base case scenario.
Given that the total number of vaccinated children is
27,990, which was estimated as the product of vaccination
coverage rate and total population of children within the
AOK PLUS data set, the sum of avoided cases was esti-
mated to be 12,143. Total costs per 1,000 children from the
SHI perspective are shown in Table 9. In the base case
scenario, the costs remained almost constant while in the
vaccine scenario they decreased from 102,074 to 86,926
Euros per 1,000 children (Fig. 3). This decrease resulted
mainly from the decline in the number of RV cases. Given
that the vaccination coverage rate has increased from 5 %
to 61 % in the observation period, we obtained the fol-
lowing estimates: the expected total cost savings attribut-
able to implementing RV vaccination in Saxony during
2007 and 2010 was 2,477 Euros per 1,000 children from
the SHI perspective. These savings already account for
vaccination costs. The proportions of outpatient and inpa-
tient costs of the total costs were about 60 % and 40 %,
respectively. The overall mean gross cost savings per
avoided case due to vaccination during the observation
period was estimated as 292 Euros per avoided case
(Table 9). The ratio between numbers of vaccinated chil-
dren and RV cases avoided due to vaccination were used to
estimate the effective costs per vaccination, which was 304
Euros (product of costs per case and ratio of vaccinated
children and RV cases avoided). Following correction for
the costs for vaccination, the net cost savings per avoided
case was estimated to be 19 Euros.
Vaccine impact due to direct and herd effects
Table 8 shows the numbers of RV cases avoided due to
herd and direct effects. The herd effect increased over time
as well as the direct effect, resulting from increase in the
vaccination coverage. An increasing herd effect is rea-
sonable due to the increasing vaccination coverage, thus
quantifying high external benefits of vaccination. While the
unprotected age groups, i.e., children aged 3 and 4 years
benefit only from the herd effect we could not quantify
protection due to the herd effect for children of ages below
2 years of age. For these children, only a direct effect was
observed and hence estimated. For children aged 2 and
Table 9 Total costs of RV infection and cost savings (in Euros) per 1,000 children from the SHI perspective
Year 2007 2008 2009 2010 2007–2010
Overall
Base case scenario 104,058 103,030 106,275 108,412 421,776
Inpatient 40,232 42,441 42,888 43,644 169,206
Outpatient 63,826 60,589 63,387 64,768 252,570
Vaccine scenario 102,074 101,452 91,638 86,926 382,090
Inpatient 39,880 41,804 35,609 36,183 153,476
Outpatient 62,195 59,647 56,029 50,743 228,614
Gross cost savings 1,984 1,579 14,637 21,486 39,686
Inpatient 353 637 7,279 7,461 15,730
Outpatient 1,631 942 7,358 14,025 23,956
Costs of vaccination 1,306 8,864 12,469 14,570 37,209
Net cost savings 678 -7,285 2,168 6,916 2,477
Gross cost savings per avoided case 304
Effective costs per vaccination 285
Net cost savings per avoided case 19
Cost savings due to direct and herd effects
Gross cost savings 1,984 1,579 14,637 21,486 39,686
Herd effect 1,984 1,579 9,417 10,458 23,438
Inpatient 353 637 3,614 3,278 7,881
Outpatient 1,631 942 5,803 7,181 15,557
Direct effect 0 0 5,220 11,028 16,248
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3 years both direct and herd effects were estimated. About
59 % of the total cost savings from 2007 to 2010 was due
to protection conferred as a result of the herd effect
(Table 9).
Sensitivity analysis
The effects of variation in the incidence rate (outpatient
and inpatient) are summarized in Table 10. We observed
an increase in total cost savings. These cost savings were
disproportionately higher in inpatients than outpatients
with increasing incidence rates. Herd effect was more
sensitive to variations in incidence rate when compared to
direct effect. In other words, to avoid a situation where the
vaccine scenario exceeded the base case scenario, an
increase in the incidence within the base case scenario may
be an appropriate instrument. In this case, the net savings
per avoided case showed the described increase. Con-
trarily, the net cost savings were negative when the inpa-
tient and outpatient incidence rate was reduced by 0.06 and
0.5 %, respectively, implying that the vaccination program
was not cost saving from the SHI perspective, as the costs
of the vaccination program exceeded the gross savings due
to implementation of the vaccination program in Saxony.
Fig. 3 Illustration of the herd effect
Table 10 Sensitivity analysis: variation of cost savings with RV inpatient and outpatient incidence rates
Variation -0.06 % -0.04 % -0.02 % Base case ?0.02 % ?0.04 % ?0.06 %
Inpatient group
Gross cost savings (in Euros) per 1,000 children 36,909 37,802 38,736 39,686 40,646 41,660 42,674
Herd effect 21,580 22,166 22,794 23,438 24,092 24,800 25,508
Direct effect 15,330 15,636 15,942 16,248 16,554 16,860 17,166
Net cost savings per avoided case (Euros) -2 5 12 19 26 34 41
Variation -0.5 % -0.4 % -0.3 % Base case ?0.3 % ?0.4 % ?0.5 %
Outpatient group
Gross cost savings (in Euros) per 1,000 children 36,981 37,522 38,063 39,686 41,485 42,102 42,718
Herd effect 21,522 21,905 22,288 23,438 24,764 25,223 25,681
Direct effect 15,459 15,617 15,775 16,248 16,721 16,879 17,036
Net cost savings per avoided case (Euros) -2 3 7 19 30 34 38
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The sickness benefits represent a significant portion of
the total costs and this amount depends on the employment
rate of mothers, the net wage and the number of days
absent from work. Although there are descriptive statistics
for each of these variables, there is still incomplete infor-
mation, specifically on the days absent from work. We
allowed this rate to vary in a range of ±1 and ±4 days per
inpatient and outpatient treatment. Table 11 shows the
effect of variation in days absent from work on the total
cost savings and cost savings per avoided case. Due to the
relative huge proportion of sickness benefit costs on the
total costs, the decrease in the number of days absent from
work, especially in case of inpatient treatments, decreases
the total cost savings. When reducing the days absent from
work by only 1 day, the net savings are negative and
implementation of vaccination is not considered to be cost
saving.
In Table 12 the results of reducing the vaccination costs
show that the net cost savings increase up to 59 Euros when
using vaccine doses from a 10-dose package.
Discussion
To the best of our knowledge the presented BIA of uni-
versal RV vaccination is the first evaluation to be based on
actual sick fund data. We made a distinction between age
groups, type of treatment sought as well as the develop-
ment of RV cases over 4 years. Most other studies have
focused on the cost-effectiveness of implementing RV
universal vaccination from different perspectives, includ-
ing quality of life weights [32, 33].
Our analysis indicates that RV vaccination in Saxony is
expected to be cost-saving from the SHI perspective. The
net cost savings are expected to be 19 Euros per avoided
case or 2,477 Euros per 1,000 children aged 0–5 years. Our
model estimated that two children must be vaccinated to
reduce the number of RV cases by one. As already indi-
cated in previous studies [18], the herd effect indeed pro-
vided a significant contribution to cost savings due to
implementation of a universal RV vaccination program in
our analysis. Regarding the total cost effect, we observed
that the herd effect finally dominated the direct effect.
From 2007 to 2010, the herd effect increased while its
relative importance decreased resulting from increasing
vaccination coverage. Given the fact that the SHI regularly
bears the cost of vaccination, the herd effect as an external
effect is not invalidated by incentives of SHIs to reduce
vaccination costs.
Previous studies in Germany have demonstrated a strong
correlation between vaccination rate and a decrease in RV
cases. Real-life vaccine impact data from Germany also
suggest a moderate decline in RV disease burden at low
and moderate levels of vaccine coverage independent of
geographic location [8, 16]. It has been suggested that the
reduction in incidence (population level) may have exten-
ded to children not eligible for vaccination, suggesting herd
protection effects as also observed at high vaccine cover-
age rates in Austria [34]. Together with recently published
data, our findings [8, 16] suggest that implementation of
routine immunization of infants against RV could result in
Table 11 Sensitivity analysis: variation of cost savings with inpatient and outpatient days absent from work
Variation -1 day -0.5 days Base case ?0.5 days ?1 day
Inpatient group
Gross cost savings (in Euros) per 1,000 children 36,394 38,040 39,686 41,332 42,978
Herd effect 21,233 22,336 23,438 24,541 25,643
Direct effect 15,161 15,704 16,248 16,791 17,335
Net cost savings per avoided case (in Euros) -6 6 19 31 44
Variation -4 days -2 days Base case ?2 day ?4 days
Outpatient group
Gross cost savings (in Euros) per 1,000 children 38,755 39,220 39,686 40,152 40,617
Herd effect 22,915 23,177 23,438 23,700 23,962
Direct effect 15,840 16,044 16,248 16,452 16,656
Net cost savings per avoided case (in Euros) 12 15 19 22 26




-5 % -10 % -15 %
Net cost savings per avoided case
(in Euros)
19 32 46 59
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significant cost-savings, especially for the healthcare payer
in Germany.
The sensitivity analysis showed that our assumptions
relating to the days absent from work influenced the final
outcomes. We expect that accounting for societal effects
like saved working hours of a parent could result in higher
estimates of cost savings than those calculated in this
framework from the health care payer perspective. Further
cost analyses, specifically on these cost components, are
thus warranted.
Given the inevitable limitations of retrospective sur-
veillance studies [35], our analysis has several limitations.
First of all, the number of RV cases and the related
medical costs were collected from only one specific
health insurance database. Although more than half of the
observed children are insured by AOK PLUS, our data
might not capture the whole picture of all RV cases in
Saxony. Moreover, we restricted the relevant age group to
children below 5 years of age because the prevalence of
RV is concentrated in this cohort. This means that the
overall contribution to the herd effect by children of
5 years and older is rather neglected from the SHI per-
spective. The sensitivity analysis showed that our results
are limited in their robustness, resulting mainly from the
construction of our base case scenario, which demon-
strated the development of RV cases without the oppor-
tunity of vaccination. Minimal variation in incidence,
especially for inpatient cases, had a strong effect on net
cost savings. The construction of the base case scenario
and, due to the fact that the vaccine scenario partially
exceeded the base case scenario, we may have underes-
timated the cost savings. Due to the distinction in inpa-
tient and outpatient cases within the base case scenario,
we assumed a constant ratio between both treatment
groups taken from the actual AOK PLUS data set.
However, these data are produced within the framework
of the vaccination program where vaccination itself could
have an influence on the inpatient and outpatient ratios.
Furthermore, we may have underestimated the benefits of
vaccination because the effect of the vaccination in 2010
may not have occurred until the following year, 2011,
which was not included in our analysis. We also excluded
any side effects of vaccination or episodes reporting
vaccine failure that would potentially decrease the cost
savings from the payer perspective. It is also important to
note that, although in our analysis we assumed RV vac-
cination to be effective, which is in-line with literature,
this assumption may have resulted in an overestimation of
the benefits. Lastly, our cost data may have been under-
estimated as we did not account for children with RV
infection that did not seek outpatient or inpatient care, but
rather were treated at home, which is commonly the case
with mild episodes of RVGE.
Conclusions
Our retrospective analysis indicates that the impact of the
recommendation for RV vaccination in Saxony has been
budget neutral if not even cost saving. Economic evalua-
tions to assess the long-term benefits of RV vaccination in
Germany as well as the potential impact on prevention of
hospitalization and the socioeconomic benefits of RV
vaccination need to be assessed further. Prospective mon-
itoring of RVGE cases is encouraged to obtain real-life
vaccine impact data.
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